Evaluating adverse effects of environmental agents in food: a brief critique of the US FDA's criteria.

OA: gold CC-BY-4.0
AI-generated summary by qwen3.7-flash, 2026-08-18

This critique of US FDA criteria for defining adverse effects in food safety highlights flaws regarding monotonic dose responses, sex-specific outcomes, and irreversibility.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by qwen3.7-flash, 2026-08-18 · read from full text

This paper provides a critical evaluation of the United States Food and Drug Administration's criteria for assessing adverse effects associated with environmental agents found in food. The authors analyze the regulatory framework to identify potential gaps or limitations in how these substances are currently judged for safety and public health impact. By reviewing existing standards, the text highlights areas where current methodologies may fall short in addressing complex environmental exposures. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

BackgroundIn the US, the Food and Drug Administration (US FDA) is charged with protecting the safety of food from both pathogens and chemicals used in food production and food packaging. To protect the public in a transparent manner, the FDA needs to have an operational definition of what it considers to be an "adverse effect" so that it can take action against harmful agents. The FDA has recently published two statements where, for the first time, it defines the characteristics of an adverse effect that it uses to interpret toxicity studies.ObjectiveIn this brief review, we examine two recent actions by the FDA, a proposed rule regarding a color additive used in vegetarian burgers and a decision not to recall fish with high levels of scombrotoxin. We evaluated the FDA's description of the criteria used to determine which outcomes should be considered adverse.OverviewWe describe three reasons why the FDA's criteria for "adverse effects" is not public health protective. These include an unscientific requirement for a monotonic dose response, which conflates hazard assessment and dose response assessment while also ignoring evidence for non-linear and non-monotonic effects for many environmental agents; a requirement that the effect be observed in both sexes, which fails to acknowledge the many sex- and gender-specific effects on physiology, disease incidence and severity, and anatomy; and a requirement that the effects are irreversible, which does not acknowledge the role of exposure timing or appreciate transgenerational effects that have been demonstrated for environmental chemicals.ConclusionsThe FDA's criteria for identifying adverse effects are inadequate because they are not science-based. Addressing this is important, because the acknowledgement of adverse effects is central to regulatory decisions and the protection of public health.
Full text 1,298 characters · extracted from epmc-fulltextxml · 5 sections · click to expand

Fn Group

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors’

LNV and RTZ wrote the first draft of the manuscript. GSP and LT provided critical edits and comments. All authors reviewed the manuscript. The author(s) read and approved the final manuscript.

Availability

Not applicable.

Declarations

LNV, RTZ, GSP and LT have received travel reimbursements from Universities, Governments, NGOs and Industry. All authors’ research has been funded by US government agencies. LNV has also received research funding from the University of Massachusetts Amherst, and NGOs including the Cornell Douglas Foundation, the Allen Family Foundation, and the Great Neck Breast Cancer Coalition. She is a scientific advisor to Sudoc LLC. RTZ’s research has been funded by government agencies in the US and EU and he serves as a scientific advisor to Sudoc LLC. GSP has received funding from the NIH and Department of Defense. LT acknowledges honoraria from Houghton Mifflin Harcourt, Audible, Paidos and Kobunsha; travel support from the Endocrine Society, WHO, UNEP, Japan Environment and Health Ministries and the American Academy of Pediatrics; as well as scientific advisory board activities for Ahimsa, Beautycounter, IS-Global and Footprint.

Associated Data

Not applicable.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: epmc-fulltextxml

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-08-16T09:21:09.727480+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Per Europe PMC